Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354

1.

Central nervous system.

Adamson DC, Rasheed BA, McLendon RE, Bigner DD.

Cancer Biomark. 2010;9(1-6):193-210. doi: 10.3233/CBM-2011-0177. Review.

PMID:
22112477
2.

Molecular biology of malignant gliomas.

Belda-Iniesta C, de Castro Carpeño J, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M.

Clin Transl Oncol. 2006 Sep;8(9):635-41. Review.

PMID:
17005465
3.

Altered molecular pathways in gliomas: an overview of clinically relevant issues.

Rao RD, James CD.

Semin Oncol. 2004 Oct;31(5):595-604. Review.

PMID:
15497113
4.

Diagnostic and prognostic molecular markers in common adult gliomas.

Rivera AL, Pelloski CE.

Expert Rev Mol Diagn. 2010 Jul;10(5):637-49. doi: 10.1586/erm.10.44.

PMID:
20629512
5.

Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.

Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG.

Neuro Oncol. 1999 Jan;1(1):14-25.

7.

Beyond grade: molecular pathology of malignant gliomas.

Sulman EP, Guerrero M, Aldape K.

Semin Radiat Oncol. 2009 Jul;19(3):142-9. doi: 10.1016/j.semradonc.2009.02.001.

PMID:
19464628
8.

Malignant gliomas.

Burton EC, Prados MD.

Curr Treat Options Oncol. 2000 Dec;1(5):459-68. Review.

PMID:
12057153
9.

[Histological and molecular classification of gliomas].

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Epub 2008 Jun 10. Review. French.

PMID:
18565348
10.
11.

Treatments for astrocytic tumors in children: current and emerging strategies.

Burzynski SR.

Paediatr Drugs. 2006;8(3):167-78. Review.

PMID:
16774296
12.

Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system.

Valera ET, Lucio-Eterovic AK, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Queiroz RG, Motta FJ, Tone LG.

J Neurooncol. 2007 Oct;85(1):1-10. Epub 2007 Apr 12.

PMID:
17429576
13.

Tumors of the central nervous system in Korea: a multicenter study of 3221 cases.

Suh YL, Koo H, Kim TS, Chi JG, Park SH, Khang SK, Choe G, Lee MC, Hong EK, Sohn YK, Chae YS, Kim DS, Huh GY, Lee SS, Lee YS; Neuropathology Study Group of the Korean Society of Pathologists.

J Neurooncol. 2002 Feb;56(3):251-9.

PMID:
12061732
14.

Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.

Marko NF, Prayson RA, Barnett GH, Weil RJ.

Genomics. 2010 Jan;95(1):16-24. doi: 10.1016/j.ygeno.2009.09.007. Epub 2009 Oct 14.

15.

Liver grafts from donors with central nervous system tumors: a single-center perspective.

Kashyap R, Ryan C, Sharma R, Maloo MK, Safadjou S, Graham M, Tretheway D, Jain A, Orloff M.

Liver Transpl. 2009 Oct;15(10):1204-8. doi: 10.1002/lt.21838.

16.

The therapy of infantile malignant brain tumors: current status?

Kalifa C, Grill J.

J Neurooncol. 2005 Dec;75(3):279-85. Review.

PMID:
16195802
17.

Exploitation of immune mechanisms in the treatment of central nervous system cancer.

Pollack IF, Okada H, Chambers WH.

Semin Pediatr Neurol. 2000 Jun;7(2):131-43. Review.

PMID:
10914414
18.

Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.

Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S.

Cancer. 2003 Dec 1;98(11):2430-9.

19.

Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?

Kuhlmann T, Gutenberg A, Schulten HJ, Paulus W, Rohde V, Bruck W.

Am J Surg Pathol. 2008 Oct;32(10):1444-53. doi: 10.1097/PAS.0b013e31817ce978.

PMID:
18685489
20.

Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.

Pollack IF, Hamilton RL, Burnham J, Holmes EJ, Finkelstein SD, Sposto R, Yates AJ, Boyett JM, Finlay JL.

Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5.

PMID:
12015841

Supplemental Content

Support Center